VK0214 / Viking Therap, Ligand - LARVOL DELTA

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Viking Therapeutics, Inc. | Recruiting ➔ Completed | Phase classification: P1b ➔ P1 | N=36 ➔ 24 | Trial completion date: Dec 2023 ➔ Nov 2024 | Trial primary completion date: Sep 2023 ➔ Oct 2024

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Pain

Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma. (PubMed, Orphanet J Rare Dis) - "Our GBM-targeted network analysis allowed us to effectively identify potential candidates for drug repurposing or repositioning. Further validation will be conducted by using other different types of biomedical and clinical data and biological experiments. The findings could lead to less invasive treatments for glioblastoma while significantly reducing research costs by shortening the drug development timeline. Furthermore, this workflow can be extended to other disease areas."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Rare Diseases • Solid Tumor

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1b | N=36 | Recruiting | Sponsor: Viking Therapeutics, Inc. | Trial completion date: Jun 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2023 ➔ Sep 2023

Trial completion date • Trial primary completion date • Genetic Disorders • Pain

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1b | N=36 | Recruiting | Sponsor: Viking Therapeutics, Inc. | Trial completion date: Feb 2023 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Genetic Disorders • Pain

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1b | N=36 | Recruiting | Sponsor: Viking Therapeutics, Inc. | Active, not recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Pain

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1b | N=36 | Active, not recruiting | Sponsor: Viking Therapeutics, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2022 ➔ Feb 2023 | Trial primary completion date: Jun 2022 ➔ Nov 2022

Enrollment closed • Trial completion date • Trial primary completion date • Genetic Disorders • Pain

A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN (clinicaltrials.gov) - P1b; N=36; Recruiting; Sponsor: Viking Therapeutics, Inc.

Clinical • New P1 trial • Pain